Manfred Rüdiger

225Ac is a promising radionuclide used for targeted alpha therapies. However, the production methods bring impurities. The long half-life of impurities raises regulatory questions around its safe use in the clinic. There are ongoing efforts to determine impurity level standards as well as waste licensing and disposal for optimal use of Actinium in the clinic.

Delve into sessions and discussions around:

• Using alpha spectrometry and other methods to determine impurity
• Sharing interactions with investigators to understand regulations
• Discussing licensing challenges for clinical use of 225Ac with 227Ac impurity
• Looking at alternative production methods
• Exploring what the future looks like for actinium in the clinic